glp-1/fgf21 agonist boehringer Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research – Caltag Medsystems iNKT Cells Induce FGF21 for

doi: 10.1016/j.ebiom.2016.10.036 425 TiderencelKAHutcheonDAZieglerJ

J.DucrosV.FortM.ArnaudJ.CoudrayC.FusselierM.FavierA.1993Reversal of selenium and zinc deficiencies in chronic hemodialysis patients by intravenous sodium selenite and zinc gluconate supplementation

Nausea (most common, typically dose-dependent and transient) Diarrhea or constipation during dose escalation Vomiting, especially when starting or increasing dose Reduced appetite and early satiety Injection site reactions (redness, bruising) Fatigue, particularly in early weeks Rare: Pancreatitis discontinue immediately with severe abdominal pain Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history) AOD-9604 is a modified C-terminal fragment (residues 176191, Tyr-hGH177-191) of human growth hormone, studied for lipolytic and anti-obesity properties

Ketamine augmentation for outpatients with treatment-resistant depression: preliminary evidence for two-step intravenous dose escalation